Medical devices, healthcare technology and the business of care
510(k) clearance · K263333

Xpert Xpress CoV-2/Flu plus

Cepheid · Decision date Oct 22, 2026

MEDTECHLEDGER EXPLANATIONK263333

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for the Xpert Xpress CoV-2/Flu plus, 510(k) number K263333, on October 22, 2026, with the application received September 22, 2026. The applicant is Cepheid of Sunnyvale, California. The device falls under regulation 866.3981, classification product code QOF with subsequent product code OOI, in the Microbiology specialty and review panel. A SESE decision is a 510(k) clearance, not a PMA approval.

The submitted document states the test runs on the GeneXpert Xpress System, described as a GeneXpert IV instrument that performs sample preparation, nucleic acid amplification and real-time fluorescent signal detection, together with a GeneXpert Hub with preloaded GeneXpert Xpress software for running tests and viewing results. The public record lists no summary statement, and the provided material does not give clinical performance data, indications wording or the specific changes relative to a prior cleared version.

The record also shows the review was not by a third party, was not a combination product, and had no authorized predetermined change control plan. Whether this filing represents a modification of an earlier Cepheid clearance is not established by the public information.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 22, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263333
Regulatory pathway
510(k) premarket notification
Applicant
Cepheid
Product code
QOF
Decision code
SESE
Decision date
Oct 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.

Applicant
Cepheid
Product code
QOF
FDA device class
2

FDA decision timeline

  1. K263333 received

    Application receipt date recorded by FDA.

  2. K263333 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QOF

Product / regulatory recordCompanyPathwayDecision dateSource
GenMark Diagnostics, Inc.510(k) clearanceOct 30, 2026FDA
Cepheid510(k) clearanceOct 2, 2026FDA
Cepheid510(k) clearanceSep 25, 2026FDA
Biofire Diagnostics510(k) clearanceSep 22, 2026FDA
Baebies, Inc.510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cepheid

Headquarters
Not reported
Brand website
cepheid.com
FDA applicant address
Sunnyvale, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records